Bisphosphonate Chelating Agent for Stable Bone Scanning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional radiolabeled bisphosphonates for bone scanning have weak bonding with tracers, leading to degradation and delayed uptake in bone tissue, which is disadvantageous for clinical use, especially in children, and require a longer time for effective imaging.
Innovation Solution
Development of compounds comprising a bisphosphonate functional group with a chelating agent that has high affinity for metal tracers like Tc-99m, Ga-67, Ga-68, In-111, Cu, or Gd, allowing rapid absorption and steady emission of ionizing radiation for improved bone imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional radiolabeled bisphosphonates are used for bone scanning, then bone imaging can be performed, but the bonding with tracer is weak causing degradation and delayed uptake (2-4 hours)
Solution Approach 1:
The patent combines bisphosphonate (for bone targeting) with chelating agents (DOTA, NOTA, DTPA) to create a composite molecule that simultaneously provides strong bone affinity and stable tracer chelation. This composite structure resolves the contradiction by integrating two functional components: the bisphosphonate group ensures rapid bone uptake while the chelating agent moiety provides stable coordination with radiometals, preventing tracer degradation and enabling imaging within hours rather than days.
2Measurement precision
If traditional radiolabeled bisphosphonates are used, then bone imaging is possible, but tracer release as impurity occurs due to weak bonding
Solution Approach 1:
The chelating agent moiety acts as an intermediary between the radiometal tracer and the bisphosphonate bone-targeting group. This intermediary component provides stable coordination chemistry with the metal tracer, preventing direct weak bonding between bisphosphonate and tracer that would lead to tracer release. The chelating agent serves as a stable bridge that maintains tracer integrity while enabling bone-specific targeting.
3Ease of operation
If traditional bisphosphonates are used, then simple structure is maintained, but clinical use is limited due to delayed uptake especially in children
Solution Approach 1:
The patent modifies the chemical parameters of traditional bisphosphonates by incorporating chelating agent moieties with different coordination properties. This parameter change in molecular structure enables rapid bone uptake kinetics while maintaining clinical practicality. The modified compounds achieve effective bone imaging within hours rather than the 2-4 hour delay of traditional agents, making them suitable for pediatric and urgent clinical applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds achieve rapid and stable bone uptake, providing high-quality imaging for bone metastasis and osteoporosis diagnosis with enhanced bone-to-muscle ratios and prolonged imaging capabilities, outperforming traditional agents in terms of labeling efficiency and image quality.
Implementation Method 1
the chelating agent moiety has high affinity for metal tracer such as radioisotope
Implementation Method 2
a radioactive substance called tracer undergoes radioactive decay, resulting in the emission of gamma ray(s) and/or subatomic particles such as alpha or beta particles
Implementation Method 3
the bisphosphonate functional group moiety has high affinity for bone tissue
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure provides a compound comprising bisphosphonate functional group and chelating agent. The bisphosphonate functional group part has high affinity for bone tissue, and the chelating agent part has high affinity for metal tracer such as radioisotope. The disclosed compound could be rapidly adsorbed onto the bone surface, and could steady emit ionizing radiation. Therefore, the disclosed compound is suitable for bone scanning technology to find abnormalities in bone.